Biofrontera Inc.
BFRI
$0.7874
-$0.0136-1.70%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.54% | 5.17% | 21.33% | 20.23% | 18.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.54% | 5.17% | 21.33% | 20.23% | 18.83% |
| Cost of Revenue | 6.67% | 7.91% | 23.04% | 15.92% | 14.88% |
| Gross Profit | 12.54% | 2.25% | 19.51% | 25.09% | 23.28% |
| SG&A Expenses | -10.73% | -9.17% | -6.62% | 7.56% | 9.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.61% | -1.50% | 3.18% | 10.18% | 11.02% |
| Operating Income | 19.39% | 11.73% | 19.40% | 2.07% | -0.48% |
| Income Before Tax | 11.83% | 51.48% | 40.41% | -68.81% | -3,208.72% |
| Income Tax Expenses | 50.00% | -14.29% | -23.81% | 42.86% | -56.25% |
| Earnings from Continuing Operations | 11.78% | 51.45% | 40.40% | -68.80% | -3,045.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.78% | 51.45% | 40.40% | -68.80% | -3,045.47% |
| EBIT | 19.39% | 11.73% | 19.40% | 2.07% | -0.48% |
| EBITDA | 19.47% | 12.04% | 19.84% | 2.07% | -0.56% |
| EPS Basic | 74.11% | 88.46% | 65.65% | -20.03% | -1,431.26% |
| Normalized Basic EPS | 67.77% | 62.61% | 53.61% | -7.63% | -339.73% |
| EPS Diluted | 72.94% | 88.46% | 65.65% | -20.00% | -1,560.94% |
| Normalized Diluted EPS | 67.77% | 62.61% | 53.61% | -7.63% | -338.13% |
| Average Basic Shares Outstanding | 255.56% | 210.46% | 138.44% | 80.42% | 46.76% |
| Average Diluted Shares Outstanding | 255.56% | 210.46% | 138.44% | 80.42% | 46.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
